OPKO Health, Inc. (NASDAQ:OPK) Receives Average Rating of “Hold” from Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been given an average recommendation of “Hold” by the six analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $1.55.

OPK has been the subject of a number of recent analyst reports. Zacks Research raised shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. HC Wainwright reissued a “buy” rating on shares of OPKO Health in a report on Wednesday, July 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, August 13th.

OPKO Health Trading Down 4.8%

Shares of OPKO Health stock opened at $1.39 on Friday. The stock has a market cap of $1.04 billion, a PE ratio of -15.44 and a beta of 1.51. The firm has a fifty day moving average price of $1.51 and a 200 day moving average price of $1.36. OPKO Health has a 1 year low of $0.98 and a 1 year high of $1.75. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07. The company had revenue of $163.58 million for the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.19) EPS. Equities research analysts predict that OPKO Health will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Securities LLC acquired a new stake in shares of OPKO Health in the second quarter valued at about $27,000. Apella Capital LLC acquired a new position in OPKO Health during the first quarter worth about $34,000. Diversify Advisory Services LLC purchased a new stake in OPKO Health during the 2nd quarter valued at about $37,000. Abel Hall LLC purchased a new stake in OPKO Health during the 1st quarter valued at about $38,000. Finally, EP Wealth Advisors LLC acquired a new stake in OPKO Health in the 2nd quarter valued at about $45,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.